MondegarAI
Euclidean Capital LLC

Q3 2024 · 13F-HR

Euclidean Capital LLCholdings as filed

Filed 2024-11-14 · accession 0001012975-24-000483

$906.8M
Reported value
12
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
78462F103SPYSPDR S&P 500 ETF TR$690.1M76.1%1,202,804CommonSOLE
46429B598INDAISHARES TR$141.9M15.7%2,425,144CommonSOLE
922042775VEUVANGUARD INTL EQUITY INDEX F$32.0M3.53%507,600CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$14.7M1.62%1,573,761CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$10.1M1.12%989,410CommonSOLE
014442107ALECALECTOR INC$6.1M0.67%1,307,858CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$3.9M0.43%2,627,643CommonSOLE
90138Q10823ANDME HOLDING CO$3.6M0.40%10,243,122CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$2.0M0.22%1,015,705CommonSOLE
75382E109RAPT THERAPEUTICS INC$1.3M0.15%657,899CommonSOLE
86889P208SRZNSURROZEN INC$1.1M0.12%87,696CommonSOLE
86889P117SRZNWSURROZEN INC$1,7600.00%170,833CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.